August 20, 2025 a 09:00 am
BMY: Analysts Ratings - Bristol-Myers Squibb Company
Bristol-Myers Squibb Company, a leader in the biopharmaceutical industry, has exhibited steady performance in the market, supported by a diverse product portfolio. Recent analyst ratings indicate a prevailing neutral sentiment, with a significant number of analysts maintaining their hold positions. Additionally, the decrease in strong buy recommendations over recent months suggests a cautious approach by the analysts, potentially due to the evolving market conditions and competitive landscape.
Historical Stock Grades
Analyzing the latest analyst ratings for Bristol-Myers Squibb Company as of August 2025:
| Recommendation Type | Number | Score |
|---|---|---|
| Strong Buy | 3 | |
| Buy | 4 | |
| Hold | 19 | |
| Sell | 1 | |
| Strong Sell | 0 |
Sentiment Development
The sentiment for Bristol-Myers Squibb has been relatively stable over recent months, with a distinct shift towards more conservative hold ratings. Key trends observed include:
- A noticeable decrease in the number of strong buy recommendations from 7 to 3 in the last year.
- A gradual increase in hold ratings, reflecting a more cautious outlook by analysts.
- The total number of recommendations has remained constant, indicating sustained analyst interest.
Percentage Trends
While there has been a reduction in strong buy recommendations, hold positions have predominantly filled the gap, signifying a shift in sentiment to a more balanced stance. Notable changes include:
- The percentage of strong buy ratings dropped from 20% to 10%, showcasing a shift to neutrality.
- Hold ratings have climbed from 60% to 70%, indicating increased caution.
- Maintaining buy ratings at approximately 20% showcases confidence amidst market fluctuations.
Overall, these changes suggest a move towards cautious optimism, with less aggressive buy recommendations.
Latest Analyst Recommendations
Recent analyst activities for Bristol-Myers Squibb reveal a predominantly hold-based sentiment, as evident from these recent updates:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-08-01 | Neutral | Neutral | Citigroup |
| 2025-07-10 | Underweight | Underweight | Morgan Stanley |
| 2025-04-28 | Equal Weight | Equal Weight | Wells Fargo |
| 2025-04-23 | Neutral | Neutral | Cantor Fitzgerald |
| 2025-04-23 | Buy | Buy | Jefferies |
Analyst Recommendations with Change of Opinion
These analyst recommendations highlight alterations in sentiment, reflecting changing perspectives:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-04-08 | Neutral | Buy | Goldman Sachs |
| 2024-12-16 | Buy | Hold | Jefferies |
| 2024-11-12 | Outperform | Market Perform | Leerink Partners |
| 2024-10-25 | Neutral | Buy | Citigroup |
| 2024-07-29 | Underweight | Equal Weight | Barclays |
Interpretation
The analysis of the current market sentiment towards Bristol-Myers Squibb suggests a period of steady interest with a cautious tilt. While the company remains resilient, the reduced strong buy ratings point towards muted expectations for explosive growth in the short-term. The increase in hold recommendations reflects a stabilizing consensus among analysts, signaling confidence in the company's sustained performance, though with a wary eye on potential market disruptions.
Conclusion
In summary, Bristol-Myers Squibb exhibits stability with a cautious outlook from analysts. The slight decrease in strong buy recommendations could suggest a conservative stance in light of market uncertainties, while consistent hold ratings indicate a sustained confidence in the company's fundamentals. Moving forward, Bristol-Myers Squibb may continue to be viewed as a strong pharmaceutical contender with solid long-term prospects, even as it navigates current market challenges.